Document Detail


Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death.
MedLine Citation:
PMID:  11592529     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Brimonidine is a lowering pressure agent currently used in glaucoma. This chronic degenerative condition is characterised by neuronal death, and an agent which offers neuroprotection may slow down or impede the progression of neuronal cell death. METHODS: The effects of brimonidine (BMD) on the short- and long-term survival of retinal ganglion cells (RGCs) after transient retinal ischaemia are reported here using a rat model. The fluorescent tracer Fluorogold (FG) was applied to both superior colliculi to retrogradely label RGCs. A ninety-minute period of ischaemia was induced and densities of surviving RGCs were estimated over time by counting FG-labelled RGCs in 12 standard regions of each retina. RESULTS: Seven days after inducing transient ischaemia, there was loss of approximately half of the RGC population. Topical pre-treatment with 0.1% or 0.5% BMD prevented ischaemia-induced RGC death. CONCLUSIONS: These results indicate that optimal neuroprotective effects against the early loss of RGCs are seen with 0.1% or 0.5% BMD. Ischaemia-induced RGC loss continued between day 7 and day 21 in the vehicle treated groups and amounted to approximately 25% of the RGC population. Topical pre-treatment with 0.1% or 0.5% BMD was also effective in reducing the slow loss of RGCs.
Authors:
M Vidal-Sanz; M P Lafuente; S Mayor-Torroglosa; M E Aguilera; J Miralles de Imperial; M P Villegas-Pérez
Related Documents :
17846059 - Multiple myeloma: causes and consequences of delay in diagnosis.
16133689 - Long-term effects on bone mineral density and bone metabolism of 6 months' treatment wi...
16136489 - Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative i...
22482379 - Microaesthetics of the smile: extraction vs. non-extraction.
8923849 - Prediction of the outcome of treatment of paget's disease of bone with bisphosphonates ...
17032149 - Effect of enzyme replacement therapy with imiglucerase on bmd in type 1 gaucher disease.
20464529 - Outcome in poor grade subarachnoid hemorrhage patients treated with acute endovascular ...
6823859 - Intermittent, continuous outpatient dobutamine infusion in the management of congestive...
19506489 - Campfire burns of the palms in crawling infants in saudi arabia: results following rele...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of ophthalmology     Volume:  11 Suppl 2     ISSN:  1120-6721     ISO Abbreviation:  Eur J Ophthalmol     Publication Date:    2001 Jul-Sep
Date Detail:
Created Date:  2001-10-10     Completed Date:  2002-02-20     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  9110772     Medline TA:  Eur J Ophthalmol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  S36-40     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Murcia, Spain. ofmmv01@fcu.um.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adrenergic alpha-Agonists / pharmacology*
Animals
Cell Survival / drug effects
Neuroprotective Agents / pharmacology*
Quinoxalines / pharmacology*
Rats
Rats, Sprague-Dawley
Receptors, Adrenergic, alpha-2 / agonists*
Reperfusion Injury / pathology,  prevention & control*
Retinal Diseases / pathology,  prevention & control*
Retinal Ganglion Cells / drug effects*,  pathology
Retinal Vessels
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Agonists; 0/Neuroprotective Agents; 0/Quinoxalines; 0/Receptors, Adrenergic, alpha-2; 59803-98-4/brimonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
Next Document:  Electrophysiological approaches for early detection of glaucoma.